Citius Pharmaceuticals (CTXR) AI Stock Analysis

• Market Cap: $24.70M
• Dividend Yield: N/A
• Average Volume (3M): 4.81M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.68
• Revenue Growth: N/A
• EPS Growth: 8.99%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -1.27
• Shares Outstanding: 11,174,466
• 10 Day Avg. Volume: 2,892,061
• 30 Day Avg. Volume: 4,814,042
• PEG Ratio: 0.04
• Price to Book (P/B): 0.25
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.54
• Enterprise Value/Market Cap: 0.62
• Enterprise Value/Revenue: 49.13
• Enterprise Value/Gross Profit: -146.02
• Enterprise Value/Ebitda: -0.09
• 1Y Price Target: $5.00
• Price Target Upside: 126.24% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 38 Underperform
• Price Target: ―

Citius Pharmaceuticals' overall stock score reflects the challenging financial performance and bearish technical indicators. The company's ongoing losses, reliance on external financing, and negative cash flows are significant concerns. The stock's downward momentum and negative valuation metrics further contribute to the low score. The biotech firm remains speculative, hinging on future revenue generation and operational improvements.

Positive Factors

Clinical Trials

Mino-Lok has demonstrated an improvement in treatment of CRBSI, achieving its primary endpoint in the Phase 3 study.

Commercialization

Citius has achieved a critical milestone in future Lymphir commercialization and patient support with the assignment of a unique, permanent HCPCS J-code by the CMS.

Regulatory Progress

The FDA provided clear, constructive, and actionable guidance for a future New Drug Application submission for Mino-Lok, supporting its pathway to regulatory approval.

Negative Factors

Financial Constraints

Citius Pharma needs to secure additional capital prior to a launch of Lymphir.

Financial Performance

The company's recent quarterly report suggests the need for additional capital in the immediate future to support operations.

Regulatory and Development Timelines

Completing the steps remaining in Mino-Lok’s pathway to regulatory approval could take some time, leading to a forecasted launch in mid-2026 instead of early 2026.

Citius Pharmaceuticals Business Overview & Revenue Model

Company Description

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

How the Company Makes Money

Citius Pharmaceuticals generates revenue through the development and commercialization of its pipeline of proprietary and collaborative pharmaceutical products. Key revenue streams include sales from FDA-approved products, licensing agreements, and strategic partnerships with other pharmaceutical companies. Citius focuses on advancing its clinical-stage products to commercialization, where it can earn revenues from product sales and royalties. Significant partnerships with healthcare organizations and research institutions also contribute to its earnings by facilitating product development and expanding market reach. Additionally, the company may receive milestone payments based on achieving specific regulatory or commercial objectives.

Citius Pharmaceuticals Financial Statement Overview

Summary

Citius Pharmaceuticals faces significant challenges typical of early-stage biotech firms, with ongoing losses and reliance on external financing. The company's financial health is stable in terms of assets and equity, but cash burn and lack of revenue generation remain critical concerns. Future success hinges on achieving revenue growth and improving operational efficiency.

Income Statement

Citius Pharmaceuticals shows a challenging income statement with negative gross profit and net income, primarily due to high operating expenses. The company has not yet generated significant revenue, with the most recent TTM (Trailing-Twelve-Months) total revenue being minimal. The EBIT and EBITDA margins are negative, indicating ongoing operational inefficiencies. Revenue growth is difficult to assess due to negligible sales figures.

Balance Sheet

The balance sheet reflects a moderate financial structure with a reasonable debt-to-equity ratio and positive equity. However, the company has been relying heavily on equity financing, as evidenced by frequent capital raises, which could dilute shareholder value. The equity ratio remains strong, indicating a solid foundation of assets relative to liabilities.

Cash Flow

Citius Pharmaceuticals has a negative free cash flow and operating cash flow, highlighting cash burn issues typical for biotechnology companies in development phases. The cash flow from financing activities indicates reliance on external funding. There is no positive free cash flow growth, and the operating cash flow to net income ratio suggests inefficiencies in converting income to cash.

Breakdown	TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement
Total Revenue	155.93K	0.00	0.00	0.00	0.00	0.00
Gross Profit	-104.92K	0.00	-194.32K	-179.68K	-164.87K	-152.36K
EBITDA	-42.53M	-38.64M	-31.77M	-32.88M	-22.88M	-17.38M
Net Income	-39.68M	-39.43M	-32.54M	-33.64M	-23.13M	-17.67M
Balance Sheet
Total Assets	120.70M	116.65M	103.61M	114.00M	142.43M	43.77M
Cash, Cash Equivalents and Short-Term Investments	1.10M	3.25M	26.48M	41.71M	70.07M	13.86M
Total Debt	204.57K	262.87K	481.25K	678.23K	855.47K	1.35M
Total Liabilities	51.78M	42.55M	12.18M	10.57M	9.65M	10.10M
Stockholders Equity	65.41M	70.08M	90.83M	102.83M	132.18M	33.67M
Cash Flow
Free Cash Flow	-26.79M	-28.20M	-29.06M	-28.36M	-64.26M	-16.93M
Operating Cash Flow	-26.79M	-28.20M	-29.06M	-28.36M	-24.25M	-16.93M
Investing Cash Flow	-5.00M	-5.00M	0.00	0.00	-40.01M	-1.83K
Financing Cash Flow	12.55M	9.97M	13.83M	0.00	120.47M	22.90M

Citius Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.21
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTXR, the sentiment is Positive. The current price of 2.21 is above the 20-day moving average (MA) of 1.24, above the 50-day MA of 0.96, and below the 200-day MA of 3.91, indicating a neutral trend. The MACD of 0.28 indicates Negative momentum. The RSI at 79.64 is Negative, neither overbought nor oversold. The STOCH value of 93.51 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTXR.

Citius Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	64 Neutral	¥342.56B	10.47	-2.86%	2.57%	11.81%	-7.17%
MRKR	44 Neutral	$18.10M	―	-97.30%	―	-3.23%	38.05%
SABS	42 Neutral	$15.98M	―	-92.35%	―	-85.48%	45.13%
PSTV	39 Underperform	$15.12M	―	249.03%	―	-14.43%	16.04%
CTXR	38 Underperform	$24.70M	―	-60.06%	―	―	8.99%
SPRB	35 Underperform	$3.06M	―	-135.33%	―	-51.32%	-1.76%
MTVA	33 Underperform	$12.69M	―	-339.64%	―	―	-75.88%